For HPV vaccines, the most influential parameters included vaccination cost per vaccinated girl, discount rate, cervical cancer incidence, proportion of deaths among incident cervical cancer cases, and vaccine efficacy.
Under conditions where the vaccination cost was $500 ,vaccinating continued to be cost-effective if the vaccine efficacy was greater than or equal to 85% and incidence rates were ≥ 9%.
When the vaccination cost was $700, a vaccine was only cost-effective when the efficacy was 85% or greater and when infection risks were at least 9%.
The cost per averted dengue episode fell below $100 in situations when the total vaccination cost was ≤ $60 and vaccine efficacy was ≥ 75%.
For rotavirus vaccines, results (in terms of ICERs) were most sensitive to vaccination cost per child, discount rate, rotavirus disease mortality, and vaccine efficacy.
In other words, the vaccination cost is that which is incurred in increasing vaccine coverage by 13.1% to reach 100% coverage.
Key input parameters are listed in Table 1.> -wrap-foot> **In the model the vaccination cost are assigned once as transition cost to vaccinated child on first and second dose i.e. only during a monthly cycle corresponding to vaccination.
For example, at an asymptomatic rate of 90% and a vaccine efficacy rate of 50%, vaccination was cost-effective at a vaccination cost of ≤ $200 (Range: ICER 21,160 11,697).
The estimation of PPR vaccination cost was based on the requirements that included purchase of PPR vaccines, cold chain equipment, vaccination supplies and equipment.
When the total vaccination cost was ≤ $1.50, vaccination was cost saving (i.e., administering vaccine actually saved money) with a vaccine efficacy of 75% or greater.
Louise Russell writes in The New England Journal of Medicine that such massive public-health measures as vaccination cost more than they save.
